NASDAQ:SRRASierra Oncology Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Sierra Oncology Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $13.50 +0.27 (+2.04 %) (As of 05/22/2020 04:00 PM ET) Add Compare Share Today's Range$13.09Now: $13.50▼$13.8450-Day Range$8.88MA: $11.23▼$13.0252-Week Range$8.55Now: $13.50▼$58.00Volume32,467 shsAverage Volume19,297 shsMarket Capitalization$140.40 millionP/E RatioN/ADividend YieldN/ABeta1.28 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Sierra Oncology, Inc., a clinical stage drug development company, is advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis and has demonstrated a differentiated therapeutic profile encompassing anemia-related benefits, as well as achieving substantive splenic volume reduction and constitutional symptom control. The company is also advancing SRA737, which is being investigated in two Phase 1/2 clinical trials primarily focused on patients with ovarian cancer; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.Read More Beat the Market (BTM) Rank™ 1.5 Analyst's Opinion Consensus RatingSierra Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.20, Sierra Oncology has a potential downside of 91.1% from its current price of $13.50.Amount of Analyst CoverageSierra Oncology has only been the subject of 1 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesSierra Oncology has received 275 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSierra Oncology has received 258 “underperform” votes. (Add your “underperform” vote.)Community SentimentSierra Oncology has received 51.59% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Sierra Oncology and other stocks. Vote “Outperform” if you believe SRRA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SRRA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSierra Oncology does not currently pay a dividend.Dividend GrowthSierra Oncology does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sierra Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders51.54% of the stock of Sierra Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.30% of the stock of Sierra Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sierra Oncology are expected to grow in the coming year, from ($9.57) to ($5.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sierra Oncology is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sierra Oncology is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSierra Oncology has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.35 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SRRA Previous SymbolNASDAQ:DNAI CUSIPN/A CIK1290149 Webwww.sierraoncology.com Phone604-558-6536Debt Debt-to-Equity RatioN/A Current Ratio19.36 Quick Ratio19.36Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.93 per share Price / Book1.51Profitability EPS (Most Recent Fiscal Year)($19.52) Net Income$-88,280,000.00 Net MarginsN/A Return on Equity-66.17% Return on Assets-51.37%Miscellaneous Employees79 Outstanding Shares10,400,000Market Cap$140.40 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:SRRA Rates by TradingView Receive SRRA News and Ratings via Email Sign-up to receive the latest news and ratings for SRRA and its competitors with MarketBeat's FREE daily newsletter. Sierra Oncology (NASDAQ:SRRA) Frequently Asked Questions How has Sierra Oncology's stock been impacted by COVID-19 (Coronavirus)? Sierra Oncology's stock was trading at $11.60 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SRRA stock has increased by 16.4% and is now trading at $13.50. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Sierra Oncology? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sierra Oncology in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Sierra Oncology. When is Sierra Oncology's next earnings date? Sierra Oncology is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Sierra Oncology. How were Sierra Oncology's earnings last quarter? Sierra Oncology Inc (NASDAQ:SRRA) announced its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($1.31) EPS for the quarter, beating the Zacks' consensus estimate of ($2.74) by $1.43. View Sierra Oncology's earnings history. What price target have analysts set for SRRA? 1 analysts have issued 1 year target prices for Sierra Oncology's stock. Their forecasts range from $1.20 to $1.20. On average, they anticipate Sierra Oncology's stock price to reach $1.20 in the next year. This suggests that the stock has a possible downside of 91.1%. View analysts' price targets for Sierra Oncology. Has Sierra Oncology been receiving favorable news coverage? News stories about SRRA stock have been trending somewhat positive on Monday, according to InfoTrie. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Sierra Oncology earned a news sentiment score of 1.5 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutSierra Oncology. Are investors shorting Sierra Oncology? Sierra Oncology saw a decline in short interest in May. As of May 15th, there was short interest totaling 45,500 shares, a decline of 36.4% from the April 30th total of 71,500 shares. Based on an average daily volume of 31,400 shares, the short-interest ratio is presently 1.4 days. Approximately 0.6% of the company's stock are sold short. View Sierra Oncology's Current Options Chain. Who are some of Sierra Oncology's key competitors? Some companies that are related to Sierra Oncology include Minerva Neurosciences (NERV), AnaptysBio (ANAB), Clovis Oncology (CLVS), Basilea Pharmaceutica (BPMUF), Urogen Pharma (URGN), Trillium Therapeutics (TRIL), Passage Bio (KROS), Xenon Pharmaceuticals (XENE), Atreca (BCEL), NewLink Genetics (NLNK), AC Immune (ACIU), BioDelivery Sciences International (BDSI), Neoleukin Therapeutics (NLTX), DURECT (DRRX) and Beyondspring (BYSI). View all competitors. What other stocks do shareholders of Sierra Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sierra Oncology investors own include Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP), Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), VBI Vaccines (VBIV), Biocept (BIOC), Co-Diagnostics (CODX), Ibio (IBIO), Selecta Biosciences (SELB) and Bellicum Pharmaceuticals (BLCM). Who are Sierra Oncology's key executives? Sierra Oncology's management team includes the following people: Dr. Nicholas R. Glover, Pres, CEO & Director (Age 50)Dr. Barbara Klencke, Chief Devel. Officer (Age 62)Dr. Mark M. Kowalski, Chief Medical Officer (Age 64)Mr. Sukhi Jagpal CA, CPA, CBV, MBA, Chief Financial Officer (Age 45)Dr. Keith E. Anderson Ph.D., Sr. VP of Technical Operations (Age 50) What is Sierra Oncology's stock symbol? Sierra Oncology trades on the NASDAQ under the ticker symbol "SRRA." Who are Sierra Oncology's major shareholders? Sierra Oncology's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vivo Capital LLC (18.43%), Orbimed Advisors LLC (14.21%), Abingworth LLP (8.43%), VR Adviser LLC (4.72%), Frazier Management LLC (1.95%) and Perceptive Advisors LLC (0.64%). Company insiders that own Sierra Oncology stock include Andrew R Allen and Barbara Klencke. View institutional ownership trends for Sierra Oncology. Which major investors are selling Sierra Oncology stock? SRRA stock was sold by a variety of institutional investors in the last quarter, including Frazier Management LLC, Perceptive Advisors LLC, and Perceptive Advisors LLC. View insider buying and selling activity for Sierra Oncology. Which major investors are buying Sierra Oncology stock? SRRA stock was acquired by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Orbimed Advisors LLC, Abingworth LLP, and VR Adviser LLC. Company insiders that have bought Sierra Oncology stock in the last two years include Andrew R Allen, and Barbara Klencke. View insider buying and selling activity for Sierra Oncology. How do I buy shares of Sierra Oncology? Shares of SRRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Sierra Oncology's stock price today? One share of SRRA stock can currently be purchased for approximately $13.50. How big of a company is Sierra Oncology? Sierra Oncology has a market capitalization of $140.40 million. The biotechnology company earns $-88,280,000.00 in net income (profit) each year or ($19.52) on an earnings per share basis. Sierra Oncology employs 79 workers across the globe. What is Sierra Oncology's official website? The official website for Sierra Oncology is www.sierraoncology.com. How can I contact Sierra Oncology? Sierra Oncology's mailing address is 2150 - 885 WEST GEORGIA STREET, VANCOUVER A1, V6C 3E8. The biotechnology company can be reached via phone at 604-558-6536 or via email at [email protected] This page was last updated on 5/25/2020 by MarketBeat.com Staff
